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Role of thalamic projection in NMDA receptor-induced 
disruption of cortical slow oscillation and short-term plasticity
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NMDA receptor (NMDAR) antagonists, such as phencyclidine, ketamine, or dizocilpine 
(MK‑801) are commonly used in psychiatric drug discovery in order to model several symptoms 
of schizophrenia, including psychosis and impairments in working memory. In spite of the 
widespread use of NMDAR antagonists in preclinical and clinical studies, our understanding 
of the mode of action of these drugs on brain circuits and neuronal networks is still limited. 
In the present study spontaneous local field potential (LFP), multi‑ (MUA) and single‑unit 
activity, and evoked potential, including paired‑pulse facilitation (PPF) in response to electrical 
stimulation of the ipsilateral subiculum were carried out in the medial prefrontal cortex (mPFC) 
in urethane anesthetized rats. Systemic administration of MK‑801 (0.05 mg/kg, i.v.) decreased 
overall MUA, with a diverse effect on single‑unit activity, including increased, decreased, or 
unchanged firing, and in line with our previous findings shifted delta‑frequency power of the 
LFP and disrupted PPF (Kiss et al., 2011). In order to provide further insight to the mechanisms 
of action of NMDAR antagonists, MK‑801 was administered intracranially into the mPFC and 
mediodorsal nucleus of the thalamus (MD). Microinjections of MK‑801, but not physiological 
saline, localized into the MD evoked changes in both LFP parameters and PPF similar to the 
effects of systemically administered MK‑801. Local microinjection of MK‑801 into the mPFC 
was without effect on these parameters. Our findings indicate that the primary site of the action 
of systemic administration of NMDAR antagonists is unlikely to be the cortex. We presume 
that multiple neuronal networks, involving thalamic nuclei contribute to disrupted behavior and 
cognition following NMDAR blockade.
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microinjection, subiculum, schizophrenia
turbances in non-human primates (Taffe et al., 2002; Buccafusco 
and Terry, 2009; Roberts et al., 2010a,b,c), therefore these phar-
macological agents have become widely used to model various 
symptoms of schizophrenia in preclinical experiments. However, 
the precise mechanism and site of action of NMDAR antagonists 
still are not fully understood (for reviews see: Gunduz-Bruce, 2009; 
Gruber et al., 2010; Kantrowitz and Javitt, 2010; Marek et al., 2010).
Some recent cognitive and electrophysiological studies sug-
gest that principal pyramidal neurons and/or interneurons of the 
medial prefrontal cortex (mPFC) are the primary targets of systemic 
administration of NMDAR antagonists (Jackson et al., 2004). In 
a previous work (Kiss et al., 2011) we studied effects of systemic 
administration of the NMDAR antagonist MK-801 on the oscil-
latory activity of the mPFC and its response to electrical stimu-
lation of the subiculum in urethane anesthetized rats. Findings 
demonstrated that MK-801 significantly modulates cortical delta 
band activity and abolishes short-term plasticity in the mPFC. 
In the present study we have made further efforts to characterize 
this NMDAR dysfunction model by analyzing parallel single-unit 
activity and field potential recordings as well as using localized 
microinjections to identify brain regions where MK-801 may exert 
its primary action.
1 IntroductIon
Schizophrenia has been linked to NMDA receptor (NMDAR) dys-
function by genetic, pharmacological, and imaging studies. Genes 
known to regulate glutamate and NMDAR function such as neu-
regulin, ERBB4, and dysbindin, have been shown to be affected 
in schizophrenia (Moghaddam, 2003; Harrison and Owen, 2003; 
Harrison and West, 2006). Abnormal glutamate metabolism has 
also been reported in schizophrenic patients (Tsai et al., 1995), 
however imaging studies have yielded conflicting results about 
brain glutamate levels. Increased glutamate levels in the left dor-
solateral prefrontal cortex (Olbrich et al., 2008), left thalamus 
(Théberge et al., 2003), prefrontal cortex, and hippocampus (van 
Elst et al., 2005), as well as decreased levels of glutamate in left 
anterior cingulate cortex (Théberge et al., 2003) and the mesial 
prefrontal cortex (Lutkenhoff et al., 2010) have been described in 
schizophrenia patients.
In support of the NMDAR dysfunction hypothesis of schizo-
phrenia, NMDAR antagonists have been shown to produce psy-
chosis  and  schizophrenia-like  cognitive  deficits  (Krystal  et  al., 
1994; Lahti et al., 1995b; Newcomer et al., 1999; Javitt et al., 2008) 
in healthy human subjects. Similar to responses seen in humans, 
NMDAR antagonist evoke sensory, behavioral, and cognitive dis-
Edited by:
Anthony A. Grace, Yale University, USA
Reviewed by:
Patricio O’Donnell, University of 
Maryland School of Medicine, USA
Daniel J. Lodge, University of Texas 
Health Science Center in San Antonio, 
USA
*Correspondence:
Tamás Kiss, Neuroscience Research 
Unit, Pfizer Global Research and 
Development, Pfizer Inc., Eastern Point 
Road, MS 8220-4335, Groton, CT 
06340, USA.  
e-mail: tamas.kiss@pfizer.comFrontiers in Psychiatry  | Schizophrenia    April 2011  | Volume 2  | Article 14  |  2
Kiss et al.  Thalamic modulation of mPFC function
2 MaterIals and Methods
2.1 anIMals and surgIcal procedures
Experiments were performed on male Sprague-Dawley rats (Harlan, 
Indianapolis,  IN,  USA;  weighing  250–320  g)  under  urethane 
anesthesia (1.5 g/kg, i.p.). Surgical procedures were conducted in 
accordance with an approved animal use protocol in compliance 
with the Animal Welfare Act Regulations and with the Guide for the 
Care and Use of Laboratory Animals, National Institutes of Health 
guidelines. The femoral vein was cannulated for administration of 
drugs. The anesthetized rat was placed in a stereotaxic frame, and 
craniotomies were performed above the region of the mPFC and 
ipsilateral CA1/subiculum. Body temperature of the rat was main-
tained at 37°C by means of a thermostatically controlled electrical 
heating pad (Harvard Apparatus). After conclusion of experiments 
animals were euthanized with an i.v. bolus of urethane.
2.2 electrophysIologIcal recordIngs
Local field potentials (LFPs) were recorded from 36 rats using a 
metal monopolar macroelectrode placed into the mPFC region 
(co-ordinates:  3.0  mm  anterior  from  bregma,  0.6  mm  lateral, 
5.0 mm ventral; Paxinos and Watson, 1986; see Figure 1). Five 
rats were implanted with an electrode in both mPFCs (co-ordinates 
are the same as above) to characterize bilateral effects of localized 
MK-801 microinjections into the mediodorsal nucleus of the tha-
lamus. All animals were allowed to stabilize for 30 min following 
electrode and cannula placement. Field potentials were amplified, 
filtered (0.1–100 Hz), displayed, and recorded at 1 kHz sampling 
rate for online and offline analysis (Spike2 software, version 7.01, 
Cambridge Electronic Design Ltd, UK).
Multi-site recordings were performed in six rats using single-
shank silicon probes (NeuroNexus Technologies), with 16 lin-
early arranged recording sites at 100 mm intervals implanted 
at the same location as the monopolar macroelectrodes in the 
other set of experiments (see above). For single-unit measure-
ment signals were amplified, high-pass filtered (700 Hz), and 
recorded at 30 kHz sampling rate (Blackrock Microsystems). 
Firing threshold was set to: − ⋅ ( ) 5 0 6745 1 2 µ / / . x  where x is the 
high-pass filtered signal and m(1/2) denotes the median (Quiroga 
et al., 2004). Spike waveforms were digitally stored when the signal 
crossed firing threshold.
Figure 1 | experimental protocol for paired-pulse stimulation of the subiculum. For a detailed description see Section 2.www.frontiersin.org  April 2011  | Volume 2  | Article 14  |  3
Kiss et al.  Thalamic modulation of mPFC function
Cellular activity
Spikes were automatically sorted offline using the Spike 2 software. 
Automatic cluster cutting was manually adjusted. Autocorrelograms 
for each cluster were calculated with 0.5 ms binning of events to set 
up criteria for including a cluster in subsequent analysis (Harris 
et al., 2000). We used the 〈N1:2〉 < 0.02* 〈N950:1000〉 rule, where Nx is 
the value for the xth bin of the autocorrelogram, and 〈Nx:y〉 denotes 
averaging bins from x to y, which selected only sufficiently clean 
clusters. For firing rate analysis, number of spikes emitted by each 
cell was counted in 1 min long bins in baseline condition and after 
MK-801 administration. Determination of whether a cell’s firing 
rate increased, decreased, or did not change was made by com-
paring binned spike numbers by two-sample, two-tailed t-tests. 
To characterize burstiness inter-spike interval histograms were 
computed and spikes occurring within 20 ms were counted. To 
establish whether burstiness of a cell increased or decreased fol-
lowing MK-801 administration the method described for firing 
rate calculation was used.
Statistical analysis was carried out in Matlab (Statistics Toolbox, 
version 7.1) or in R (R Development Core Team, 2008).
3 results
In line with our previous experiments (Kiss et al., 2011) we have 
shown that in urethane anesthetized rats, spontaneous LFP recorded 
from the mPFC mainly consists of a large amplitude (peak-to-peak 
≈0.5 mV), regular, ≈2 Hz frequency oscillation termed high-delta 
(1.5–2.5 Hz band) oscillation (Figure 2). Electrical stimulation of 
the ipsilateral subiculum evokes a response with approximately 
25 ms latency (Figure 3B, left), and a second pulse, delivered 
100 ms later evokes a second, approximately three times bigger 
response with similar, but not identical temporal characteristics. 
This enhancement of response amplitude is termed PPF.
Systemic administration of MK-801 (0.05 mg/kg, i.v.), a non-com-
petitive, use-dependent NMDAR antagonist significantly changed 
cortical EEG delta activity by increasing its amplitude and reducing 
its frequency into the 0.5 to 1.5-Hz frequency range, termed here as 
low-delta oscillation (Figure 2). Furthermore, the amplitude distribu-
tion of the spontaneous LFP changed from a symmetrical to a skewed 
distribution (c.f. insets on Figure 3A left and right). Concomitantly, 
MK-801 significantly reduced PPF primarily by increasing the ampli-
tude of the first evoked response (c.f. Figures 3Ca,Cc).
3.1 systeMIc adMInIstratIon of MK-801 reduces ppf by MultIple 
effects, IncludIng ModIfIcatIon of ongoIng actIvIty
To better characterize factors contributing to the above changes 
following systemic administration of MK-801, and to enable us to 
speculate about the cellular and network mechanisms underlying the 
generation of PPF of responses evoked by stimulating the subicu-
lum, we further analyzed separate parts of the evoked field potentials.
Firstly, in control condition, we found that amplitude of the 
response  evoked  by  the  first  stimulus  (P1)  tends  to  be  larger, 
when stimulation coincided with high LFP values (LFP@s1). For 
this, raw traces were transformed to zero mean, unity variance 
time series, and individual responses where LFP@s1 ≤ 0 mV and 
responses where LFP@s1 > 0 mV were separately averaged and the 
two resulting responses compared to show a significant difference 
between first responses in the two averages (P and P control
high
control
low 1 1 ; 
2.3 paIred-pulse stIMulatIon
Parallel to LFP measurements a twisted-wire stimulation electrode 
was placed in the CA1/subiculum (co-ordinates: 6.3 mm posterior 
from bregma, 5.2 mm lateral, and 8.0 mm ventral; Paxinos and 
Watson, 1986) of all rats in this study. The paired-pulse stimu-
lus consisted of two square-pulses, duration 0.1 ms, amplitude 
0.1–1 mA, paired-pulse interval 100 ms, inter-stimulus interval 
10 s, generated continuously from a Master 8 stimulator (APMI, 
USA). Intensity of the stimulus was adjusted so that the first evoked 
response amplitude was ≈100 mV (Figure 1).
2.4 localIzed MK-801 MIcroInjectIon
In addition to the recording and stimulating electrodes placed in 
the ventral mPFC and ipsilateral subiculum of the hippocampus 
respectively, a 30 gage stainless steel cannula was placed in both the 
ipsi- and contralateral mPFCs (co-ordinates from bregma: 3.4 mm 
anterior, 0.6 mm lateral, 5.0 mm ventral; Paxinos and Watson, 1986) 
in four animals, or in the ipsilateral mediodorsal thalamic nucleus 
(MD; co-ordinates from the bregma: 2.3 mm posterior, 0.8 mm 
lateral, and 6.0 mm ventral; Paxinos and Watson, 1986) in five 
animals for localized infusion of MK-801, and in four animals for 
saline control. Baseline cortical LFP activity, and corresponding 
evoked response amplitudes were recorded bilaterally using mac-
roelectrodes (see Section 2.2). Animals were subsequently infused 
with 1% MK-801 (in saline). A microdialysis infusion pump (WPI 
SP101i) and a 250-ml Hamilton syringe were used to infuse at the 
rate of 1 ml/min. Details of infusions are described in Sections 3.3 
and 3.4.
2.5 hIstologIcal processIng
After animals were euthanized at conclusion of electrophysiol-
ogy experiments, brains were rapidly removed and frozen fresh 
on dry ice. Brains were sliced into 20 mm sections at −18°C 
using a microtome and mounted on 25 mm × 75 mm × 1 mm 
microscope slides. Sections were fixed for 5 min in 4% para-
formaldehyde, rinsed in dH2O, then stained with 0.5% Cresyl 
Echt Violet for Nissl substance. The slides were then rinsed in 
dH2O, dehydrated, cleared in xylene, and coverslipped. Slides 
were scanned in Aperio ScanScope XT (Aperio Technologies 
Inc. Vista, CA, USA) at 10×.
2.6 data analysIs
LFP and PPF
Electrically evoked responses and quantitative EEG analysis were 
performed by means of waveform averages and Fast Fourier 
Transformation, respectively. For offline data analysis, LFP data 
was read into the MATLAB software [The Mathworks, Natick, 
MA, USA, version 7.8 (R2009a)] using the sigTOOL toolbox 
(Lidierth,  2009).  For  data  epoching,  filtering,  and  time-fre-
quency decomposition, the EEGLAB Matlab toolbox (Delorme 
and Makeig, 2004) was used, while other operations were car-
ried out by custom made scripts. Delta power spectrum density 
of the LFP was calculated between 0.1 and 4 Hz. Paired-pulse 
facilitation (PPF) was defined as the ratio of the amplitude of 
the first evoked response (P1) and the second evoked response 
(P2). Experiments where the PPF in control was less than 1.5 
were rejected from the analysis.Frontiers in Psychiatry  | Schizophrenia    April 2011  | Volume 2  | Article 14  |  4
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Figure 2 | effect of systemic administration of MK-801 (0.05 mg/kg, i.v.) on 
field potential oscillations in the medial prefrontal cortex. Before drug 
administration the LFP is characterized by a regular, approximately 2 Hz 
frequency, 0.5 mV amplitude rhythm, termed high‑delta oscillation. Effects of 
systemic MK‑801 administration include increasing the power of a lower 
frequency, less regular, larger amplitude oscillation (low‑delta oscillation), and 
consequently decreasing relative high‑delta power. A representative time‑
frequency plot and two, 30 s long LFP traces are shown.
A
B
Ca Cb Cc Cd
Figure 3 | effect of systemic administration of MK-801 on LFP and 
different components of the evoked response. Left panels show measures in 
control condition, right panels after administration of MK‑801 (0.05 mg/kg, i.v.). 
(A) Representative traces showing 20 s of ongoing LFP before (left) and after 
(right) MK‑801 administration, insets show amplitude histograms of 600 s long 
epochs calculated in the two conditions. Note that not only the frequency and 
amplitude of the LFP oscillation changed after MK‑801 administration, but the 
LFP tends to take positive values with higher probability. A pair of typical evoked 
field potentials are shown on (B), red curves are averages of evoked responses 
where the stimulation occurred at greater than or equal to 0 mV potential, while 
blue is where the LFP was less than 0 mV at the time of stimulation. (Ca,Cc) 
show dependence of the amplitude of the first component of the evoked 
response (P1) on the LFP value at the time of the first stimulation (LFP@s1). To 
compare data from different animals (n = 36) on the same plot, each raw LFP 
trace was transformed to zero mean, unity variation signal. Blue dots correspond 
to data derived from averaging 60 responses where LFP@s1 ≤ 0 mV, red where 
LFP@s1 > mV, black lines connect points from the same animal, blue and red 
crosses give mean (location), and SD (length) of data in both directions. (Cb,Cd) 
show dependence of the LFP voltage occurring at the time of the second 
stimulus (LFP@s2) on LFP@s1. For more details, see text.www.frontiersin.org  April 2011  | Volume 2  | Article 14  |  5
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  systemic MK-801 administration. For this experiment four rats 
were implanted with two cannulae, one in the ipsi- and an other 
in the contralateral mPFC (relative to the recording site) for local 
infusion of MK-801. After a 5-min baseline period MK-801 was 
injected into the ipsilateral side by a microdialysis pump at 1.0 ml/
min rate for 5 or 10 min, resulting in the injection of 50 or 100 mg 
of MK-801. Following an approximately 5 min long delay a second 
injection of MK-801 was delivered into the contralateral mPFC 
using the same parameters as that of the ipsilateral mPFC injection. 
LFP and evoked responses were recorded.
Figure 5A shows a spectrogram calculated from a representa-
tive LFP recorded during mPFC injection. Changes in ongoing 
oscillations relative to baseline were not observed at any time or 
treatment domain. This was further confirmed by calculating the 
ratio of power contained in the 1.5 to 2.5-Hz range (high-delta 
interval) to the total power in baseline condition, after ipsilateral 
injection of MK-801, and after bilateral injection, respectively. A 
one-way ANOVA did not show significant differences between 
groups (p = 0.101; Figure 5B). Similarly, P1 and P2 components, 
as well as PPF of responses evoked by stimulation of the subiculum 
did not change significantly (one-way ANOVA for PPF: p = 0.352; 
Figure 5C; for the first response amplitude: p = 0.255; for the second 
response: p = 0.302). To ensure potency of the used MK-801 solu-
tion, a group of rats were injected intravenously and the previously 
described systemic effects were seen (data not shown).
3.4 localIzed MK-801 InjectIon Into the MedIodorsal nucleus 
of the thalaMus has sIMIlar effects to systeMIc MK-801 
adMInIstratIon
Effects of systemic administration of MK-801 are characterized by 
specific changes in delta oscillation (Figure 2, also see Kiss et al., 
2011). It is presumed that cortical delta rhythm has two different 
sources, one originating in the neocortex (Amzica and Steriade, 
1998), the other in the thalamus (Steriade et al., 1993). Our previous 
findings (Kiss et al., 2011) showed that blocking action potential 
generation in the mediodorsal nucleus of the thalamus by local 
lidocaine microinjections reproduced changes evoked by systemic 
MK-801 administration. Localized MK-801 microinjections into 
the mediodorsal nucleus of the thalamus (Figure 6) evoked similar 
effects to those seen after intravenous MK-801 administration or 
localized lidocaine microinjection. MK-801 injection localized to 
the MD resulted in a significant decrease of relative high-delta 
power on the ipsilateral side and a trend to decrease on the contral-
ateral side in the mPFC (Figure 7D). These changes in high-delta 
are accompanied by an increase in absolute (Figure 7A) and relative 
low-delta power (Figure 8A). Local MD injection of MK-801 signif-
icantly increased the P1 component of the evoked response without 
increasing the P2 component (Figure 7B; paired t-test, p = 0.0499, 
5% confidence interval for 〈PIMD injection − PIBaseline〉 = [20.67 129.35]
mV). PPF in all animals decreased after drug administration, how-
ever significance was not reached (paired t-test p = 0.1705) due to 
big variation within baseline values (Figure 7C).
In contrast, physiological saline injection into the MD failed 
to reproduce changes seen after MK-801 administration (n = 4). 
Spectrograms  calculated  from  ipsilateral  mPFC  LFPs  did  not 
show the characteristics observed after systemic or MD-localized 
MK-801 administration, although a small but significant decrease 
paired, two-tailed t-test: p = 7.4·10−9, 5% confidence interval for 
〈 − 〉 = P P 1 1 0 140 23 control
high
control
low [ . . ]; Figure 3Ca). Systemic MK-801 
administration  increases  the  probability  of  high  LFP  values 
(Figure 3A, right panel inset), thus by modifying the ongoing oscilla-
tion, MK-801 increases the possibility to evoke larger first responses, 
and as a result decreased PPF. Moreover, besides this indirect effect, 
MK-801 also exerts a direct effect on the first response. Comparing 
average first response amplitudes of control and MK-801 groups, a 
significant difference was found in both high and low cases (paired, 
two-tailed t-test: 〈 − 〉 = P P MK-801
low
control
low 1 1 0 330 58 5 [ . . ], %  confidence 
interval, p = 2.7.10-8,  〈 〉 P1 P1 MK-801
high
control
high − =[ . . ], % 0 641 03 5  confi-
dence interval, p = 2.7.10-8, cf. Figures 3Ca,Cc).
Secondly, calculating the difference (∆P) between the potential at 
the trough of the first response and the potential at the time of the 
second stimulation (LFP@s2; see also Figure 3B, left) sheds some light 
at processes taking place in re-polarization of stimulated cells. In con-
trol condition, ∆P depends heavily on LFP@s1 (∆Phigh = 0.8 ± 0.4 mV; 
∆Plow = 1.4 ± 0.4 mV). Importantly, as re-polarization after deeper 
polarization is faster than after shallower polarization, by the time 
of  the  second  stimulus,  the  LFP  reaches  similar  values  in  both 
high and low cases (paired, two-tailed t-test: p = 7.9·10−7, 5% con-
fidence  interval  for  〈 − 〉 = LFP LFP @s2,control
high
@s2,control
low [ . . ]; 0 080 16  
Figures 3B,Cb). Interestingly enough, after MK-801 administration 
the corresponding potential differences are not changed significantly 
( , ∆ ∆ ∆ ∆ P P P P control
high
MK-801
high
control
low
MK-801
low and ≈ ≈  paired, two-tailed t-test at 
5% significance level). As the first pulse is larger after MK-801 as   discussed 
above, this results in significantly lower LFP@s2 values compared to   control 
( p = ⋅ 〈 − 〉 =
− 2 7 10 0 61 1
13 . , [ . . ]; LFP LFP @s2,control
low
@s2,MK-801
low  p = 1.2⋅10−16,
LFP LFP @s2,control
high
@s2,MK-801
high − =[ . . ]; 0 260 53  cf. Figures 3Cb,Cd). Thus 
by modifying the ongoing oscillatory state, MK-801 modifies the envi-
ronment in which both the first and the second stimulus are delivered, 
which in turn results in decreased PPF and ultimately, altered infor-
mation processing.
3.2 systeMIc adMInIstratIon of MK-801 results In decreased 
spIKIng actIvIty
A group of six rats were implanted with multi-site silicone elec-
trodes to record cellular activity in the mPFC. Comparing the total 
number of spikes [multi-unit activity (MUA)] recorded in a 10-min 
long period before and 5 min after systemic MK-801 administration 
(0.05 mg/kg, i.v.) revealed a significant decrease of spiking activity 
(Figure 4A; two-sample, two-tailed t-test, p = 0.0128, 5% confi-
dence interval for 〈MUAbaseline − MUAMK-801〉 = [0.09 0.75] spikes/s).
Besides measuring MUA, a total of 148 cells were clustered from 
these recordings. Clustering spikes revealed, that although the overall 
spiking activity decreases, individual cells activity (Figures 4B–D) 
decrease [n = 66 (44.6%)], increase [n = 30 (20.3%)], or remain 
unchanged [n = 52 (35.1%)]. Furthermore, changes in burstiness 
was also evaluated. We found that 15 cells (10.1%) had decreased, 
25 cells (16.9%) had increased, and 108 (73.0%) had unchanged 
burstiness based on our definition (see Section 2.6).
3.3 MIcroInjectIons of MK-801 localIzed In the mpfc do not 
effect delta-frequency lfp oscIllatIon or ppf
Our next efforts targeted the localization of the site of action 
of  MK-801.  We  first  tested  whether  local  microinjection  into 
the mPFC evokes the electrophysiological effects observed after Frontiers in Psychiatry  | Schizophrenia    April 2011  | Volume 2  | Article 14  |  6
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of the subiculum. Detailed analysis of the relationship between 
field potential changes and reduction in PPF revealed that multiple 
mechanisms contribute to decreased PPF; one of the significant 
contributing factors is a skewed distribution of positive-negative 
values in field potentials after MK-801. Furthermore, effects of 
systemic administration of MK-801 has been reproduced by local 
microinjection of the drug into the mediodorsal nucleus of the tha-
lamus, but not the mPFC, indicating that effects of non-competitive 
NMDAR antagonists on cortical function involve complex neuronal 
circuitry mechanisms.
A large body of literature suggests that the mPFC is a key region 
involved in the expression of pathological behavior and impairment 
of cognitive functions, such as working memory, in schizophrenic 
patients (Winn, 1994; Knable and Weinberger, 1997). NMDAR 
antagonists phencyclidine (PCP) and ketamine, which are capable 
of evoking cognitive deficits in healthy volunteers similar to schizo-
phrenic patients (Luby et al., 1959; Krystal et al., 1994; Malhotra 
et al., 1996), have been shown to primarily affect activity of the 
PFC (Lahti et al., 1995a; Breier et al., 1997). Animal models using 
in    high-delta  component  in  these  experiments  was  observed 
(Figures 9A,D). However, when compared to MK-801 adminis-
tration, saline evoked a significantly smaller decrease in power in 
this frequency band (Figure 8B). This small decrease of cortical 
high-delta power might be a result of non-drug related effects of 
microinjection such as changes in brain temperature, changes in 
ionic concentration of the interstitial matrix or increased extracel-
lular pressure. Furthermore, no change was observed in param-
eters of the evoked responses following saline injection into MD 
(Figures 9B,C).
4 dIscussIon
The present findings demonstrate that systemic administration of 
the NMDAR antagonist MK-801 in anesthetized rats changes regu-
lar cortical field potential oscillation by altering power distribution 
within the delta band and modifies firing activity of the majority 
of cortical neurons. Parallel to changes in cortical delta oscilla-
tion, MK-801 also decreases short-term plasticity as indicated by 
a reduction in PPF of the cortical response elicited by stimulation 
A B
C D
Figure 4 | Change of cellular activity in response to MK-801 administration. 
Multi‑unit activity (A), reflecting an average change of spiking activity showed a 
significant (p = 0.0128) decrease (mean ± SEM shown) following drug treatment 
(0.05 mg/kg MK‑801, i.v.), however, individual cells with decreased (B), 
unchanged (C), or increased (D) firing activity were found. (B–D) show raster 
plots of individual cells (baseline spike counting period is highlighted in green, 
MK‑801 was given at the beginning of the white period, which was 5 min long, 
spikes for MK‑801 treatment were counted in the region highlighted in red).www.frontiersin.org  April 2011  | Volume 2  | Article 14  |  7
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in this frequency range and an increase in relative power in the 0.5 
to 1.5-Hz lower delta band. This change in delta power seems to be 
one of the mechanisms underlying the simultaneous reduction in 
PPF. Furthermore, alteration in relative power in delta band activity 
led to a right-skewed field potential distribution, indicating a more 
hyperpolarized membrane potential of cortical neuronal network. 
In accordance with this hypothesis, our present findings reveal that 
parallel to changes in field potential MK-801 decreased overall neu-
ronal firing activity. Although the average firing rate of all recorded 
neurons in the mPFC was reduced, individual neurons showed 
varied responses to MK-801, including increased, decreased, or 
unchanged firing rate.
The  most  widely  accepted  hypothesis  on  MK-801-induced 
changes  in  cortical  neuronal  activity  is  based  on  observations 
obtained from recordings of cortical neurons in freely moving rats. 
Systemic administration of MK-801 has been reported to increase 
activity of presumed pyramidal neurons by reducing activity of 
GABAergic  interneurons  (Homayoun  and  Moghaddam,  2007). 
These observations are in line with a notion that NMDAR antagonists 
preferentially block NMDARs on interneurons, particularly those 
NMDAR antagonists induce sensory (Mansbach and Geyer, 1989; 
Miller et al., 1992), behavioral (Freed et al., 1980; Moghaddam 
and Adams, 1998; Jentsch and Roth, 1999), and cognitive (Heale 
and Harley, 1990; Verma and Moghaddam, 1996) disturbances – 
some of which involve the mPFC – that resemble schizophrenia 
symptoms. Thus, several studies have focused on identifying the 
precise mechanism localized within the mPFC, through which 
NMDAR antagonists disrupt function of this brain region (Sebban 
et al., 2002; Lorrain et al., 2003; Jodo et al., 2005; Homayoun and 
Moghaddam, 2007; Kargieman et al., 2007). However, studies using 
microinjections of NMDAR antagonists into the mPFC are not 
conclusive about its effectiveness. For example, in a series of studies 
Suzuki et al. (2002) were unable to reproduce the long-lasting acti-
vation of mPFC and augmented locomotion induced by systemic 
administration of PCP with direct injection of PCP into the mPFC.
Our findings demonstrate significant changes in activity of the 
mPFC in response to systemic administration of MK-801 in ure-
thane anesthetized rats. In line with our previous observations (Kiss 
et al., 2011), MK-801 decreased regular oscillatory activity in the 
1.5 to 2.5-Hz delta band as reflected by a decrease in relative power 
Figure 5 | Localized bilateral administration of MK-801 into the mPFCs 
does not have effects on LFP oscillations or PPF. (A) Spectrogram for a 
representative experiment does not show the characteristic appearance of a 
strong low‑delta component characteristic of systemic MK‑801 injection (cf. 
Figure 2; insets show two 20 s long LFP traces from the shown region of the 
recording, each including two stimulation periods). (B) Boxplot of relative 
high‑delta‑frequency component of the power spectrum (middle black bar is 
median, green (baseline), and red (MK‑801) boxes show 25th and 75th 
percentiles, whiskers are most extreme data points). (C) Boxplot representing 
changes in PPF .Frontiers in Psychiatry  | Schizophrenia    April 2011  | Volume 2  | Article 14  |  8
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Figure 6 | MD cannula location. Stereotaxic diagram (left) and histological reconstruction (right) of the injection cannula (shown as a black bar on left) targeting the 
mediodorsal nucleus of the thalamus.
Figure 7 | Localized administration of MK-801 into the mediodorsal nucleus 
of the thalamus results in changes similar to those observed following 
systemic drug administration. (A) Spectrogram of contralateral (upper) and 
ipsilateral (lower) mPFC LFP . Microdialysis pump was turned on after 10 min 
baseline recording for 5 min. Onset of activity similar to i.v. MK‑801 injection was 
shortly after the pump was turned off in this particular experiment. Insets show 
characteristic LFP traces from highlighted regions of the ipsilateral signal. 
(B) Similar to systemic MK‑801 administration, P1 component of the evoked 
response increased significantly after MD microinjection (p = 0.0218), while P2 did 
not change significantly. (C) PPF showed a tendency to decrease, but changes did 
not reach significance (individual animal data also shown). Ongoing LFP delta 
oscillation (D) changed similar to systemic MK‑801 administration: the relative high 
frequency delta component significantly decreased (p = 0.0499) in the ipsilateral 
mPFC, and showed a tendency to decrease (p = 0.1761) in the contralateral mPFC.www.frontiersin.org  April 2011  | Volume 2  | Article 14  |  9
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A B
Figure 8 | Comparison of LFP oscillation properties following 
intra-thalamic (MD) microinjection of saline or MK-801. (A) A significant 
increase in low‑delta power after local injection of MK‑801 (p = 0.004) but 
not saline into the MD. As noted at Figures 7D and 9D both MK‑801 and 
saline induced a significant decrease in high‑delta power, however, as 
shown here on panel (B) the magnitude of the change following MK‑801 is 
significantly larger (p = 0.04, left‑tailed t‑test) than that induced by saline 
injection.
Figure 9 | Localized saline administration into the mediodorsal nucleus of 
the thalamus does not enhance low-delta activity and fails to replicate effects 
of localized MK-801 administration. (A) A representative spectrogram of 
ipsilateral mPFC LFP . Insets show characteristic LFP traces from highlighted regions. 
(B,C) MD‑localized saline injection did not influence paired‑pulse facilitation. (D) 
Ongoing LFP high‑delta oscillation power significantly (p = 0.0134) decreased after 
saline injection, however the magnitude of the change was significantly smaller 
compared to the decreased observed after MK‑801 administration (see Figure 8).
containing parvalbumin (Xi et al., 2009), innervating pyramidal 
neurons. However, recent findings have revealed a much more com-
plex picture of neuronal effects of MK-801. Firing activity of wide-
spiking putative pyramidal neurons was   suppressed or   facilitated in 
approximately equal proportion, similar to the response of fast-firing 
putative interneurons by MK-801 in freely moving rats perform-
ing cognitive tasks (Christian et al., 2010). Our findings in urethane 
anesthetized animals indicate a diverse response of cortical neurons Frontiers in Psychiatry  | Schizophrenia    April 2011  | Volume 2  | Article 14  |  10
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under urethane anesthesia compared to the freely moving case might 
lie in the difference between the activity profile of interneuron firing, 
especially a difference in the activity of thalamic reticular GABAergic 
neuron firing. Microinjections in our experiments were targeted 
into the mediodorsal nucleus of the thalamus. A relatively high vol-
ume and high dose of MK-801 was applied and the latency of the 
observed effects were variable. Injection of MK-801 in the same 
dose and volume into the mPFC did not elicit changes in cortical 
oscillation or PPF, indicating a local site of action following MD 
administration. However, the exact site of action of MK-801 in the 
thalamus is not certain and the possibility that MK-801 impacts neu-
ronal activity in the thalamic reticular formation cannot be excluded. 
The differences in thalamic neuron activity between awake and anes-
thetized animals could explain differences in response to NMDAR 
antagonism in these respective paradigms. For example, thalamic 
reticular neurons are depolarized in awake animals (Pinault, 2004), 
whereas they are hyperpolarized under urethane anesthesia (Yen and 
Shaw, 2003; Pinault, 2004). Consequently, use-dependent NMDAR 
antagonists would impact neuronal activity differently depending 
on the vigilant state. While in freely moving animals antagonism 
on interneurons’ NMDARs is more pronounced, in anesthetized 
animals NMDARs on principal cells might primarily be blocked, 
resulting in differences in electrophysiological measures.
As referred to before, it is unclear whether activity of all principal 
neurons are increased after NMDAR antagonism even in awake 
rats, or if the main action of these drugs lies with their disrup-
tive effects on complex neuronal circuitries. Interestingly enough, 
using proton magnetic resonance spectroscopy Lutkenhoff et al. 
(2010) recently found that glutamate was significantly lower in the 
mesial prefrontal gray matter of patients with schizophrenia and 
unaffected co-twins than in healthy controls. This also supports a 
more diverse pathophysiology of schizophrenia than an enhanced 
glutamate transmission and a reduced feed-forward inhibition 
of principal neurons as has been suggested by previous models. 
Furthermore, if the above speculation is true it could have an impact 
on the timing of administration of drugs, which directly (ketamine, 
mementine) or indirectly (AMPA potentiators) modulate NMDAR-
mediated neurotransmission; these drugs might influence brain 
activity differently depending on the vigilant state.
Taken together, present results show that local application of the 
use-dependent NMDAR antagonist MK-801 into the mediodorsal 
nucleus of the thalamus modulates ongoing field oscillation and 
concomitantly PPF in the mPFC in urethane anesthetized rats. 
Based on these findings we hypothesize that disruptive effects of 
NMDAR antagonists on cognitive function are exerted primarily in 
the thalamus and consequently via the thalamo-cortical circuitry.
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to MK-801, including excitation. In contrast, it has been reported that 
local application of PCP inhibits the majority of deep mPFC neurons 
(Gratton et al., 1987) whereas locally applied MK-801 inhibits or 
maintains the activity of mPFC but fails to induce excitation (Jodo 
et al., 2005). We hypothesize that non-competitive NMDAR antago-
nists might affect NMDARs on both principal cells and interneurons 
in a similar fashion and the net effect of NMDAR blockade results 
from changing the balance of firing in these two populations. A 
possible explanation for different changes of firing rates seen after 
NMDAR antagonism in different experimental conditions could 
be a difference in baseline firing dependent upon behavioral state. 
For example, during active wakefulness firing rate of interneurons 
is typically much higher than that of pyramidal cells, while under 
anesthesia this might not be the case.
Present results together with previous findings indicate that 
changes  in  mPFC  electrophysiology  and  function  induced  by 
NMDAR antagonists are downstream effects, involving modulation 
of activity of afferent pathways to mPFC (Lorrain et al., 2003) such as 
the hippocampus (Jodo et al., 2005) or one or multiple thalamic sub-
regions. Here we are proposing a critical role of subcortical regions, 
particularly the thalamus, in NMDAR antagonism-induced schizo-
phrenia-like symptoms. In fact, our current findings provide direct 
evidence for the involvement of the thalamo-cortical projection in 
MK-801-induced changes in cortical activity. Thus, microinjection 
of MK-801 targeted into the MD thalamic nucleus, but not into the 
mPFC, elicited changes reminiscent of systemic administration of 
the drug, leading to altered relative delta power distribution, and 
reduced PPF. It is well established that the thalamus plays a critical 
role in processing and integrating sensory information relayed to the 
cortex (Steriade et al., 1997) and can regulate the state of information 
processing in different cortical regions (Mumford, 1991; Hirata and 
Castro-Alamancos, 2010). A number of thalamic areas have been 
shown to be affected in schizophrenia (Sharp et al., 2001; Clinton 
and Meador-Woodruff, 2004; Alelú-Paz and Giménez-Amaya, 2008; 
Lisman et al., 2010) and the primary brain region where a decrease 
in cell number has been shown in schizophrenic brains is the MD 
(Pakkenberg, 1990, 1992, 1993; Popken et al., 2000; Young et al., 
2000; Byne et al., 2002). In line with these findings, blockade of 
NMDARs in the thalamus by MK-801 (Tomitaka et al., 2000) or by 
PCP (Santana et al., 2011) has been shown to activate and injure 
principal cells in several cortical regions.
There are differences when comparing our findings in urethane 
anesthetized animals with previous results in freely moving ani-
mals. Firstly, we observed a decrease of action potential generation 
at the population level, while in freely moving animals MK-801 
induced an increase in pyramidal cell firing (Jackson et al., 2004; 
Homayoun et al., 2005; Lisman et al., 2008). Secondly, burstiness 
in our experiments increased slightly, however, in freely moving 
animals a decrease was observed (Jackson et al., 2004). Finally, 
the LFP amplitude histogram became right-skewed after MK-801 
administration, which was interpreted to be due to a more hyperpo-
larized LFP, possibly resulting from glutamate hypofunction, while 
in freely moving animals PCP (Moghaddam and Adams, 1998) or 
ketamine (Lorrain et al., 2003) induced increased glutamate release. 
Based on the working hypothesis that changes induced by NMDAR 
antagonists in the mPFC are downstream effects originating from 
the thalamus, a possible explanation for the differences observed www.frontiersin.org  April 2011  | Volume 2  | Article 14  |  11
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